APA

Robak T., Huang H., Jin J., Zhu J., Liu T., Samoilova O., Pylypenko H., Verhoef G., Siritanaratkul N., Osmanov E., Pereira J., Mayer J., Hong X., Okamoto R., Pei L., Rooney B., van de Velde H. & Cavalli F. (20191231). Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study. : Leukemia & lymphoma.

Chicago

Robak Tadeusz, Huang Huiqiang, Jin Jie, Zhu Jun, Liu Ting, Samoilova Olga, Pylypenko Halyna, Verhoef Gregor, Siritanaratkul Noppadol, Osmanov Evgenii, Pereira Juliana, Mayer Jiri, Hong Xiaonan, Okamoto Rumiko, Pei Lixia, Rooney Brendan, van de Velde Helgi and Cavalli Franco. 20191231. Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study. : Leukemia & lymphoma.

Harvard

Robak T., Huang H., Jin J., Zhu J., Liu T., Samoilova O., Pylypenko H., Verhoef G., Siritanaratkul N., Osmanov E., Pereira J., Mayer J., Hong X., Okamoto R., Pei L., Rooney B., van de Velde H. and Cavalli F. (20191231). Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study. : Leukemia & lymphoma.

MLA

Robak Tadeusz, Huang Huiqiang, Jin Jie, Zhu Jun, Liu Ting, Samoilova Olga, Pylypenko Halyna, Verhoef Gregor, Siritanaratkul Noppadol, Osmanov Evgenii, Pereira Juliana, Mayer Jiri, Hong Xiaonan, Okamoto Rumiko, Pei Lixia, Rooney Brendan, van de Velde Helgi and Cavalli Franco. Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study. : Leukemia & lymphoma. 20191231.